Rigel director exercises options, sells 4K shares

Rigel Pharmaceuticals director Walter H. Moos reported option and share transactions.

(Moderate)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Rigel Pharmaceuticals director Walter H. Moos reported option and share transactions. On February 20, 2026, he exercised a stock option for 4,000 shares of common stock at $24.00 per share through a derivative exercise or conversion.

On the same date, he sold 4,000 shares of common stock in an open-market or private transaction at $36.36 per share. After these transactions, he directly owned 12,722 shares of Rigel Pharmaceuticals common stock. The reported numbers reflect a prior one-for-ten reverse stock split.

Insider Trade Summary

Exercise and Sale: 4,000 shares ($49K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider MOOS WALTER H

Role Director

Sold 4,000 shs ($145K)

Approx. gross sale proceeds $145K

Approx. exercise cost $96K

Approx. pre-tax spread $49K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	4,000	$0.00	$0.00
Exercise	Common Stock	4,000	$24.00	$96K
Sale	Common Stock	4,000	$36.36	$145K

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 12,722 shares (Direct)

Footnotes (2)

F1. These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
F2. The shares vested monthly over twelve (12) months from the grant date of May 11, 2016.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did RIGL director Walter H. Moos report?

Walter H. Moos reported exercising options for 4,000 Rigel Pharmaceuticals shares at $24.00 and selling 4,000 shares at $36.36. Following these transactions, he directly owned 12,722 common shares, according to the Form 4 filing.

Did Walter H. Moos buy or sell Rigel (RIGL) stock in this Form 4?

The Form 4 shows both an acquisition and a sale. Moos acquired 4,000 shares via stock option exercise at $24.00 per share and then sold 4,000 common shares at $36.36 per share on the same date.

How many Rigel (RIGL) shares does Walter H. Moos own after these transactions?

After completing the reported transactions, Walter H. Moos directly owned 12,722 shares of Rigel Pharmaceuticals common stock. This figure reflects adjustments for a prior one-for-ten reverse stock split noted in the filing footnotes.

What stock option activity by Walter H. Moos is disclosed for Rigel (RIGL)?

The filing discloses that Moos exercised a stock option covering 4,000 shares of Rigel common stock at $24.00 per share. The transaction is classified as an exercise or conversion of a derivative security on February 20, 2026.

At what price did Walter H. Moos sell Rigel Pharmaceuticals (RIGL) shares?

Moos sold 4,000 shares of Rigel Pharmaceuticals common stock at $36.36 per share. The transaction is identified as a sale in the open market or a private transaction, reported under transaction code "S" in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/24/2026 - 04:58 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOOS WALTER H

(Last)

(First)

(Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/20/2026		M		4,000⁽¹⁾	A	$24⁽¹⁾	16,722	D
Common Stock	02/20/2026		S		4,000	D	$36.36	12,722	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$24⁽¹⁾	02/20/2026		M			4,000⁽¹⁾	⁽²⁾	05/11/2026	Common Stock	4,000⁽¹⁾	$0	0	D

Explanation of Responses:

1. These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

2. The shares vested monthly over twelve (12) months from the grant date of May 11, 2016.

	/s/ Raymond Furey (Attorney-in-Fact)	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR